XML 13 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 30, 2022
Current assets:    
Cash and cash equivalents $ 464,480 $ 501,195
Short-term investments 802,335 807,273
Trade receivables, net 232,818 214,784
Inventory 28,635 33,299
Prepaid expenses and other current assets 62,259 62,211
Total current assets 1,590,527 1,618,762
Long-term investments 838,615 756,731
Property and equipment, net 115,004 110,624
Deferred tax assets, net 231,115 231,110
Goodwill 63,684 63,684
Right-of-use assets and other 303,523 290,578
Total assets 3,142,468 3,071,489
Current liabilities:    
Accounts payable 25,994 32,667
Accrued compensation and benefits 68,213 77,158
Accrued clinical trial liabilities 59,260 65,072
Rebates and fees due to customers 52,486 50,350
Accrued collaboration liabilities 22,960 20,188
Other current liabilities 110,704 78,924
Total current liabilities 339,617 324,359
Long-term portion of deferred revenues 6,724 6,582
Long-term portion of operating lease liabilities 194,694 190,170
Other long-term liabilities 73,495 61,951
Total liabilities 614,530 583,062
Commitments and contingencies (Note 10)
Stockholders' equity:    
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 320,253 and 323,951 at June 30, 2023, and December 31, 2022, respectively 320 324
Additional paid-in capital 2,530,869 2,536,849
Accumulated other comprehensive loss (14,437) (14,521)
Retained earnings (Accumulated deficit) 11,186 (34,225)
Total stockholders' equity 2,527,938 2,488,427
Total liabilities and stockholders' equity $ 3,142,468 $ 3,071,489